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Although  the passive transfer of T  cell-mediated immunity to growth of a  tumor 
implant is relatively easy to demonstrate,  it has proven extremely difficult  to dem- 
onstrate  that  passively  transferred,  tumor-sensitized  T  cells  have  any  therapeutic 
effect  against  an  established  growing  tumor  (1).  The  most  likely  reason  for  the 
refractoriness of established immunogenic tumors to adoptive immunotherapy with 
tumor-sensitized T  cells was supplied by previous publications  from this laboratory 
(2,  3),  which  show  that  progressive growth  of an  immunogenic  tumor evokes the 
generation  in  its host of a  T  cell-mediated mechanism of immunosuppression. The 
existence of this mechanism of immunosuppression was revealed in two ways: first, by 
showing that although passively transferred,  tumor-sensitized T  ceils failed to cause 
the  regression  of tumors  growing  in  normal  mice,  they  caused  the  complete  and 
permanent regression of the same-sized tumors growing in mice that had been made 
T  cell deficient by thymectomy and irradiation;  and second, by demonstrating that 
failure of passively transferred, sensitized T  cells to cause the regression of tumors in 
normal mice was associated with the presence in these mice of splenic T  cells capable 
of inhibiting adoptive T  cell-mediated regression of tumors growing in T cell-deficient 
mice.  On  the  basis of this  and  other evidence,  it  was  hypothesized  (2,  3)  that  the 
progressive growth of an immunogenic tumor evokes the generation of a  state of T 
cell-mediated concomitant immunity that undergoes T  cell-mediated negative regu- 
lation before enough effector T  cells are produced to destroy the tumor. It was further 
hypothesized (4) that any attempt to cause tumor regression by the passive transfer of 
tumor-sensitized T  cells represents an attempt to superimpose an adoptive immune 
response on an already ongoing concomitant immune response that may be undergo- 
ing negative regulation, depending on the size of the tumor. If this line of reasoning 
is  correct,  it  should  follow  that  any  treatment  that  prevents  the  generation  of 
concomitant immunity and of the suppressor T cells that negatively regulate it, should 
facilitate the antitumor function of passively transferred, tumor-sensitized T  cells. 
The  purpose  of this  paper is  to  show  that  a  cyclophosphamide-treated,  tumor- 
bearing  recipient  can  substitute  for a  T  cell-deficient,  tumor-bearing  recipient  for 
demonstrating that an established tumor can be caused to completely regress by the 
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passive transfer of tumor-sensitized T  cells. It will show that, whereas passive transfer 
of tumor-sensitized T  cells has no effect on the growth of an immunogenic fibrosar- 
coma,  and  whereas  cyclophosphamide  treatment  causes  only a  temporary  halt  in 
tumor progression, combination therapy with  cyclophosphamide plus sensitized T 
cells causes the tumor to completely and permanently regress. It will show, in addition, 
that  tumor regression caused by combination therapy with cyclophosphamide and 
immune cells can be completely inhibited by intravenous infusion of cyclophospha- 
mide-sensitive suppressor T  cells from the spleens of tumor-bearing donors. 
Materials and Methods 
Mice.  Specific-pathogen-free BALB/c and CB6F1  (BALB/c ×  C57BL/6)  mice were sup- 
plied  by  the  Trudeau  Institute Animal Breeding Facility. They were  free  of known viral 
pathogens, as evidenced by the results of routine serological screening performed by the Animal 
Diagnostic Testing Service of Microbiological Associates, Bethesda, MD. 
Tumor.  The  methylcholanthrene-induced, Meth  A  fibrosarcoma,  syngeneic in  BALB/c 
mice, was originally obtained from Dr. Lloyd J. Old of the Memorial Sloan-Kettering Cancer 
Center, New York.  It was  grown to large number as  an ascites  in the peritoneal cavities of 
BALB/c  mice,  harvested  and  washed  in phosphate-buffered  saline  (PBS),  resuspended  in 
Fisher's medium (Grand Island Biological  Co.,  Grand Island, NY)  containing 20% fetal calf 
serum and 10% dimethyl sulfoxide,  and cryopreserved in small vials over liquid nitrogen. For 
each experiment, a vial was thawed, the tumor cells washed in PBS, and 2 ×  106 implanted in 
the peritoneal cavities of CB6F1 mice. Tumor cells were harvested 6 d later in PBS, washed in 
PBS, and resuspended appropriately for implantation. Tumors were initiated in the right hind 
footpad by intrafootpad injection of 106 or 2 x  106 tumor cells in a  volume of 0.5  ml PBS. 
Tumor growth  was  monitored against time by measuring changes  in the  thickness of the 
footpad with dial calipers. 
Adoptive Immunization.  Donor mice were immunized against the Meth A tumor by injecting 
them  intradermally with  2  ×  10  s  Meth  A  cells  admixed  with  100  /~g  of  formalin-killed 
Corynebacterium parvum (Burroughs Wellcome, Greenville, NC). This is known (5) to result in a 
9-d  period  of tumor growth  followed  by  complete  tumor  regression.  The  onset  of tumor 
regression  is associated with immunity to growth of a tumor implant and with the presence in 
the spleen of T  cells capable of passively transferring immunity to a tumor implant (5). The 
immunized mice were used as donors 3-4 wk after tumor regression.  Their spleens were diced 
into small pieces and gently pushed and washed through a 60-mesh stainless screen with PBS. 
The resulting cell suspension was triturated with a pasteur pipette to break up clumps, passed 
through six layers of sterile surgical gauze, and washed and resuspended in PBS for intravenous 
infusion. Recipient mice received 1.5 ×  l0  s spleen cells in a volume of 0.5 ml. 
Anti-Thy-l.2  Treatment.  Spleen cells were incubated at  10°C for 30 min at 5 ×  107/ml in a 
1  : 1,000 dilution of monoclonal IgM anti-Thy-  1.2 antibody supplied as ascites fluid by Accurate 
Chemical & Scientific Corp., Westbury, NY. The cells were washed in PBS and incubated at 
the same concentration in a  1:15 dilution of rabbit serum from the same supplier for 30 rain at 
37°C. After a further wash in PBS, the cells were resuspended for intravenous infusion. 
Cyclophosphamide. Cyclophosphamide (Cytoxan) was purchased from Mead Johnson & Co., 
Evansville, IN. It was  dissolved  in sterile water and injected intravenously in a  dose  of 100 
mg/kg, unless otherwise stated. 
Results 
Failure  of Cyclophosphamide  or  Immune  Cells  Alone  to  Cause  Tumor  Regression.  That 
cyclophosphamide has a  limited therapeutic effect against a  Meth A  footpad tumor 
is shown in Fig.  1, where it can be seen that a  dose of 160 mg/kg given on day 5 or 9 
of tumor growth caused only a  small degree of tumor regression over several days, 
after which the tumor resumed growing at its original rate. Fig.  1 shows, in addition, ROBERT J.  NORTH  1065 
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FIG.  1.  Effect  of intravenous injection of 160 mg/kg of cyclophosphamide  on the growth of a 6-d 
(left panel) and a 9-d (right panel) Meth A tumor growing in normal mice or in mice given 650 rad 
of gamma irradiation just before tumor cell implantation. A smaller antitumor effect was obtained 
with the 100 mg/kg dose used in subsequent experiments. Means of five mice per group. A  tumor 
control; I-q, 650 rad; -~?-,  cyclophosphamide;  O, 650 rad plus cyclophosphamide. 
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Fic. 2.  Failure of immune spleen cells infused intravenously to effect the growth of a tumor 
implant given 2 (0) or 4 (-~)-) d earlier. Only a small antitumor effect was observed even when 
immune cells were infused at the same time as giving the implant  (1"-1). Means of five mice per 
group. A, control. 
that the antitumor effect of cyclophosphamide was the same in mice that had been 
given 650 rad of whole-body gamma-irradiation 1 h before tumor implantation.  This 
result allows the conclusion that the antitumor effect was caused by the direct action 
of the drug on the tumor, and was not caused by a  capacity of the drug to enhance 
an antitumor immune response. The same results were obtained with the  100 mg/kg 
dose of cyclophosphamide routinely employed in the experiments that follow. How- 
ever, the result of giving this smaller dose of the drug was to cause tumor growth to 
plateau for several days, rather than to cause tumor regression. 
In keeping with previous findings (2, 3), an intravenous infusion of 1.5 ×  108 spleen 
cells from the tumor immune donor mice had no effect on the growth of a 4-d tumor 
(Fig. 2). In fact, this number of immune spleen cells had only a slight inhibitory effect 
on tumor growth when infused within 1 h  of implanting tumor cells. In other words, 
the standard number of immune spleen cells used in this study was incapable even of 
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Complete Tumor Regression after Combination Therapy with  Cyclophosphamide and Immune 
Cells.  The proceeding results showed that treatment with cyclophosphamide caused 
only temporary regression of an established Meth A fibrosarcoma, whereas intravenous 
infusion of immune cells has no effect at all.  The purpose of the experiments  in this 
section was to determine whether combination therapy with cyclophosphamide plus 
immune cells would result in complete tumor regression. The design of the experiments 
was based on the knowledge (2,  3)  that passive transfer of immune T  cells can cause 
the  regression  of the  Meth  A  tumor  growing  in  mice  made  T  cell  deficient  by 
thymectomy and irradiation,  but not in normal mice. It was reasoned, therefore, that 
any  treatment  that  causes  either  a  temporary  or  permanent  deficiency  of T  cells 
should allow passively transferred immune T  cells to express their antitumor function. 
That cyclophosphamide treatment  facilitates the expresion of adoptive immunother- 
apy against  an  established  tumor is  shown  in  Fig.  3,  where  it  can  be seen  that  an 
injection of 100 mg/kg of cyclophosphamide on day 4 of tumor growth followed  1 h 
later by intravenous  infusion of 1.5  ×  108 immune spleen  cells resulted  in complete 
tumor  regression  in  all  mice.  No  regrowth  of tumors  was  observed  during  a  60-d 
period  of  observation.  In  contrast,  and  in  agreement  with  the  findings  above, 
cyclophosphamide alone had only a  marginal effect on tumor growth, and  immune 
cells  alone had  no effect at  all.  A  previous publication  (2)  showed  that  spleen  cells 
which on passive transfer cause regression of established  Meth A  tumors are T  cells, 
as  evidenced  by  their  destruction  by  treatment  with  anti-Thy-l.2  antibody  and 
complement. 
It  was  found,  in  addition,  that  combination  therapy  with  cyclophosphate  and 
immune cells is capable of causing the regression of relatively large Meth A  tumors. 
It  can  be  seen  in  Fig.  4  that  giving  100  mg/kg  of cyclophosphamide  1  h  before 
infusing immune spleen  cells caused  the complete regression of 3-, 6-, and  even  9-d 
tumors. It should be pointed out that a  9-d footpad tumor is three times the size of a 
normal  footpad,  and  that  cyclophosphamide alone  contributed  only marginally  to 
the  regression  of tumors  of this  size.  Therefore,  the success of combination  therapy 
does  not  depend  on  the  ability  of cyclophosphamide to reduce  the  tumor  below  a 
certain critical size. 
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FIG. 3.  Combination therapy consisting of intravenous injection of 100 mg/kg of cyclophospha- 
rnide followed 1 h later by intravenous infusion of 1.5 X l0  s spleen cells from tumor-immune donors 
resulted, after a delay, in complete and permanent  tumor regression. Combination therapy  was 
given on day 4 of tumor growth. Means of five mice per group. A, tumor control; IS], cyclophospha- 
mide; <)-, cyclophosphamide plus normal cells; C), cyclophosphamide plus immune cells. ROBERT  J.  NORTH  1067 
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F]~.  4.  Evidence that combination therapy (arrows) with cyclophosphamide and immune spleen 
cells results in the complete regression of 3-, 6-, and 9-d tumors. The 9-d tumors were more than 
three times the size of a  normal  footpad. Means of five mice per group.  A, tumor control; <~-, 
cyclophosphamide; O, immune cells; f"l, cyclophosphamide plus immune cells. 
r0. 
1  60- 
.4,' 
=~4a, 
~Z0  u" 
e  '¢2~/-  • 
°AYS 
FIG.  5.  Evidence that  tumor regression caused by combination therapy with cyclophosphamide 
and immune spleen cells (O) is completely abolished by intravenous infusion 24 h later of 1.5 X  10  s 
spleen cells from donors with established 12-d tumors (l~), hut not by the same number of spleen 
ceils from  normal  donors  (I).  Means of five mice per group.  A  control;  <~-, immune ceils;  A, 
cyclophosphamide. 
Tumor Regression Caused by  Combination Therapy with  Cyclophosphamide and Immune T 
Cells is Inhibited by Splenic T  Cells from  Donors with Established Tumors.  The results in 
the preceding section, in conjunction with those previously published  (2,  3)  can be 
interpreted  as  showing  that  cyclophosphamide  treatment  of tumor-bearing  mice 
facilitates adoptive immunotherapy with  immune T  cells by either eliminating  or 
preventing the development of a  tumor-induced mechanism  that  prevents intrave- 
nously  infused  immune  T  cells  from  expressing  their  antitumor  function.  If this 
tumor-induced mechanism is mediated by a population ofcyclophosphamide-sensitive 
suppressor  T  cells,  it  should  be  possible  to  counteract  the  therapeutic  action  of 
cyclophosphamide and  immune cells by passively transferring splenic T  cells from 
donors with established tumors. This possibility was tested by measuring the fate of 
tumors  in  mice  given  combination  therapy  with  cyclophosphamide and  immune 
spleen cells on day 4 of tumor growth, followed 24 h later by an intravenous infusion 
of splenic cells from mice bearing  12-d tumors. It can be seen in Fig. 5 that passive 1068  CYCLOPHOSPHAMIDE-FACILITATED  ADOPTIVE  IMMUNOTHERAPY 
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Flo.  6.  Evidence that  the spleen cells from tumor-bearing mice, which inhibit tumor regression 
caused by combination therapy with cyclophosphamide and immune cells, are T  cells. It can be 
seen  that  the  suppressive action  of tumor  bearer's  spleen  cells  was  completely eliminated  by 
treatment with anti-Thy-l.2 antibody and complement (15]). Combination therapy was given on 
day  4,  and  suppressor  cells  on  day  5.  Means  of five  mice  per  group.  ©,  tumor  control;  A;~-, 
cyclophosphamide plus immune cells; A, cyclophosphamide plus immune cells plus suppressors. 
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F/o.  7.  Evidence that tumor regression caused by cyclophosphamide and immune cells (A), and 
the inhibition of this regression by spleen cells from 12-d tumor-bearing donors can be demonstrated 
in syngeneic BALB/c mice. Combination therapy was given on day 4, and suppressor cells on day 
5 (0). Means of five mice per group. ©, control; F-l, cyclophosphamide; A  immune cells. 
transfer of spleen cells from  12-d tumor-bearing donors completely inhibited tumor 
regression caused by combination therapy with cyclophosphamide and immune cells. 
The tumors behaved as though the mice had been given cyclophosphamide alone. 
That the spleen cells responsible for this suppressive action were T cells is shown by 
the results in Fig. 6, where it can be seen that their suppressive function was totally 
eliminated by incubating them with anti-Thy-l.2 antibody plus complement. Fig. 5 
serves  to  illustrate  the  additional  important  finding  that  an  infusion  of the  same 
number of normal spleen cells had no effect on the outcome of combination therapy. 
Therefore, suppressor cells were generated in response to tumor growth: 
The purpose of the results in Fig.  7 is to show that  cyclophosphamide-facilitated 
adoptive T  cell-mediated tumor regression and its suppression with spleen cells from 
tumor-bearing donors can be demonstrated in syngeneic BALB/c mice. These results 
serve to discount the criticism that  the preceding results and  those that  follow are 
peculiar to the tumor growing in semisyngeneic CB6F1 hosts. 
Suppressor  T  Cells,  but Not Immune  T  Cells,  are Cyclophosphamide  Sensitive.  The results ROBERT J.  NORTH  1069 
in the preceding sections are consistent with the interpretation that treatment of the 
tumor-bearing host  with  cyclophosphamide  facilitates  adoptive  T  cell-mediated 
regression  of  its  established  tumor  by  eliminating a  cyclophosphamide-sensitive 
population of suppressor  T  cells  that  inhibits the  antitumor function of passively 
transferred immune T  cells.  If this  is  so,  the  T  cells in tumor-bearing donor mice 
capable of suppressing cyclophosphamide-facilitated adoptive immunotherapy should 
be destroyed by treating the tumor-bearing donors with cyclophosphamide. This is 
shown in Fig. 8, where it can be seen that treating donors bearing 12-d Meth A tumors 
with 100 mg/kg cyclophosphamide 24 h before harvesting their spleen cells completely 
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Fro.  8  Evidence  that cyclophosphamide destroys the T ceils in 12-d tumor bearers that inhibit 
tumor  regression caused by combination  therapy  with  cyclophosphamide and  immune  cells. 
Treating the tumor-bearing mice with 100 mg/kg of cyclophosphamide  24 h before harvesting their 
spleen ceils completely ablated the capacity of the spleen cells to inhibit tumor regression (11). 
Means of five mice per group. (O), tumor control; -<~-, cyclophosphamide plus immune cells; A, 
cyclophosphamide plus immune cells plus suppressor. 
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FIG. 9.  Treating  immune donors with  100 mg/kg  of cyclophosphamide had  no effect on the 
capacity of their spleen cells harvested 24 h later to cause tumor regression in cyclophosphamide- 
treated  recipients, Means of five mice per group. A  tumor control; [S], cyclophosphamide; 0, 
cyclophosphamide  plus immune cells;  ©, cyclophosphamide  plus cyclophosphamide-treated  immune 
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ablated the capacity of their spleen cells to suppress adoptive T  cell-mediated tumor 
regression in cyclophosphamide-treated recipients. The completeness of destruction of 
suppressor cells by cyclophosphamide is indicated by the additional knowledge that 
no suppression was observed, even though  it  took three spleen equivalents of cells 
from the cyclophosphamide-treated tumor-bearing donors to equal  the  number of 
spleen cells (1.5 X  l0  s) obtained from tumor-bearing control donors. 
In  contrast  to  the  cyclophosphamide-sensitivity of suppressor  T  cells,  immune 
spleen cells  from tumor-immune  donors were highly resistant  to the  drug.  This  is 
shown in Fig. 9, where it can be seen that the treatment of immune donor mice with 
100 mg/kg of cyclophosphamide 24 h before harvesting their spleen cells had no effect 
on the capacity of spleen cells to cause tumor regression in cyclophosphamide-treated 
recipients. This result was obtained with one spleen equivalent (5 X  107) or with three 
spleen equivalents (1.5 X 10  s) of cells from cyclophosphamide-treated immune donors. 
Discussion 
This paper shows that an established methylcholanthrene-induced tumor, the Meth 
A fibrosarcoma, can be caused to completely and permanently regress in a syngeneic 
or semisyngeneic host by combination therapy consisting of intravenous injection of 
100 mg/kg of cyclophosphamide followed 1 h later by intravenous infusion of splenic 
T  cells from tumor immune donors. In contrast, infusion of immune cells alone had 
no effect on tumor growth, and  cyclophosphamide alone caused only a  temporary 
halt in tumor progression. Thus, because cyclophosphamide alone had only a marginal 
effect on tumor growth, most of the destruction of the tumor caused by combination 
therapy could be attributed to the antitumor action of passively transferred immune 
T  cells.  These results indicate, therefore, that cyclophosphamide facilitates adoptive 
immunotherapy  by  eliminating  a  mechanism  from  the  tumor-bearing  host  that 
normally prevents passively transferred tumor-immune T  cells from expressing their 
antitumor function. On the other hand, the success of the combination therapy did 
not depend on the capacity of cyclophosphamide to reduce the tumor burden below 
a certain critical size, because therapy was successful against small tumors, as well as 
against large tumors that were little effected by the direct action of cyclophosphamide. 
An explanation for the mechanism of cyclophosphamide-facilitated adoptive im- 
munotherapy requires a  consideration of the results of studies of tumor-induced, T 
cell-mediated immunosuppression already published from this laboratory (2). It was 
shown that progressive growth of the Meth A fibrosarcoma (2) and P815 mastocytoma 
(3) in their syngeneic hosts is associated with the generation of a mechanism of T  cell- 
mediated  immunosuppression  that  blocks attempts to cause the regression of these 
tumors by adoptive immunotherapy with tumor-sensitized T  cells.  Indirect evidence 
for this conclusion consisted of the demonstration that passive transfer of sensitized T 
cells  failed  to  cause  the  regression  of established  tumors,  unless  the  tumors  were 
growing in recipient mice made T cell deficient by thymectomy and irradiation. This 
indicated that  normal tumor-bearing mice generate a T  cell-dependent mechanism 
that  prevents intravenously infused  immune cells  from expressing their antitumor 
function.  Direct  evidence for the  existence of this  mechanism  of T  cell-mediated 
immunosuppression in normal tumor bearers was revealed by an experiment which 
showed that prior intravenous infusion of splenic T  cells from these mice prevented 
passively transferred immune T  cells from causing the regression of tumors in T  cell- ROBERT J.  NORTH  1071 
deficient  recipients.  It  was  hypothesized,  therefore,  that  progressive growth  of an 
immunogenic tumor eventually results in the generation of a state of immunosuppres- 
sion that  is mediated by suppressor T  cells. It was  hypothesized more recently (4), 
that this state of immunosuppression represents negative regulation of a concomitant 
antitumor immune response that undergoes decay before enough effector T  cells are 
generated to:cause regression of the tumor. 
The experiments reported in this paper were designed to further investigate this 
hypothesis. It was  predicted that, because passively transferred immune T  cells are 
capable of causing tumors to regress in T  cell-deficient recipients, any treatment that 
either temporarily or permanently prevents the generation of T  cell-mediated con- 
comitant  immunity and  its  negative  regulation  should  allow passively transferred 
immune T  cells to express their antitumor function. The results presented here leave 
little doubt that cyclophosphamide facilitates adoptive immunotherapy in this way. 
They show that tumor regression caused by combination therapy with cyclophospha- 
mide and immune T  ceils can be completely inhibited by the intravenous infusion of 
splenic T  cells from tumor-bearing donors, but not from normal donors. They also 
show that  this suppressor activity of the splenic T  cells from tumor-bearing donors 
can be completely ablated by treating the donors by cyclophosphamide. This repre- 
sents direct evidence that  mice bearing the Meth A  fibrosarcoma contain a  tumor- 
induced population of cyclophosphamide-sensitive T  cells which suppresses the anti- 
tumor action of passively transferred immune T  cells. 
In contrast, cyclophosphamide treatment of immune donors had no effect whatso- 
ever on the capacity of their splenic T  cells to cause tumor regression. This could be 
taken  as evidence that  cyclophosphamide selectively destroys suppressor ceils.  It  is 
important  to  realize, however, that  the  mode[  used  in  this study  is  artificial with 
regards to the immune response to a growing tumor, because the immune cells were 
obtained,  not  from mice responding  to a  progressive tumor,  but  from  immunized 
donors, the tumors of which had been caused to regress 3-4 wk earlier by intralesional 
C. parvum therapy (5). It then seems safe to assume that the immune cells were memory 
or helper cells, and that they were resistant to cyclophosphamide treatment because 
they were nonreplicating. This cannot be used as evidence, therefore, that cytolytic 
effector T  cells are cyclophosphamide resistant. The possibility remains that replicat- 
ing cytolytic T  cells that  might  be  generated  as  part  of the concomitant immune 
response to a growing tumor (6) will be susceptible to the dose of cyclophosphamide 
used to eliminate suppressor T  cells.  In this connection, we have failed to find a dose 
of cyclophosphamide that will cause the complete regression of the Meth A fibrosar- 
coma in mice that are expressing concomitant immunity to an implant of this tumor. 
There are numerous publications showing that appropriately timed pretreatment 
with  cyclophosphamide can  result  in  the  generation  of augmented  levels  of cell- 
mediated immunity to a  variety of antigens  (7).  Only in a  few cases, however, has 
directed evidence been  supplied  to show  that  the  augmenting  action  of the  drug 
depends on its ability to preferentially eliminate suppressor T  cells.  For example, it 
has  been  demonstrated  that  cyclophosphamide-augmented  production  of T  cells 
cytolytic for SV40-transformed syngeneic cells  (8)  and  for TNP-coupled syngeneic 
cells and allogeneic spleen cells (9) can be abolished by passively transferring normal 
splenic T  cells  before giving  the  immunogens.  Because  these  are  examples  of the 
elimination of precursors of suppressor T cells, their exact relevance to the T cells that 1072  CYCLOPHOSPHAMIDE-FACILITATED ADOPTIVE  IMMUNOTHERAPY 
suppress the cyclophosphamide-facilitated expression of adoptive antitumor immunity 
described here is as yet unkown. It seems unlikely, however, that the drug facilitates 
the expression of adoptive antitumor immunity by eliminating suppressor precursors, 
because its facilitating effect was not abolished by infusing normal T  ceils, but only 
by infusing cyclophosphamide-sensitive T  cells from donors with established tumors. 
The relationship between cyclophosphamide-sensitive suppressor precursors and an- 
tigen-differentiated suppressor T  cells is currently under study. Consideration also is 
being given to the possibility that the suppression of antitumor immunity is achieved 
by two types of suppressor T cells, only one of  which is destroyed by cyclophosphamide, 
as appears to be the case of the suppression of contact  sensitivity (10)  and  delayed 
sensitivity  to  certain  haptens  (11).  Moreover,  discovering  the  mode  of  action  of 
suppressor T  cells will depend on a  more detailed knowledge of the events that need 
to occur in the tumor-bearing recipient of tumor-immune T  cells before adoptive T 
cell-mediated tumor regression is expressed. In this regard, there is evidence (4)  that 
the  passively transferred  tumor-immune T  cells  used  in  this  study,  being  memory 
cells,  do  not  themselves cause  tumor  regression,  but  impart  to  the  tumor-bearing 
recipient the capacity to generate a secondary cytolytic T  cell response. Experiments 
performed thus  far (4)  indicate that  it is this adoptive secondary cytolytic response 
that fails to occur when immune T  cells are infused into normal tumor bearers, and 
when immune T  cells are infused  into T  cell-deficient or cyclophosphamide-treated 
tumor bearers that are also infused with suppressor T cells from normal tumor bearers. 
~I'he model ofcyclophosphamide-facilitated, adoptive T cell-mediated tumor regres- 
sion described in this paper is reminiscent of the model described some years ago by 
Fefer  (12)  who  passively transferred  immunity  to  the  highly  immunogenic  MSV- 
induced  sarcoma  growing  progressively  in  mice  that  were  immunosuppressed  by 
cycloph0sphamide. This is immunologically more appealing than combination ther- 
apy models, which  consist  of injecting sensitized T  cells locally into  ascites tumors 
that have been substantially destroyed to an unknown  degree by cyclophosphamide 
or othe  r  agents.  Because the Meth A  fibrosarcoma growing as a  soild tumor is only 
slightly  susceptible  to  the  direct  cytotoxic  action  of  the  drug,  immunologically 
mediated regression can be measured in terms of the destruction  of a  known tumor 
mass.  Moreover,  models  of immunotherapy that  consist  of injecting  immune  cells 
directly into a tumor site fail to investigate one of the most important functions that 
immune T  cells or their progeny must perform to be useful in tumor immunotherapy: 
the capacity to migrate from the intravascular compartment to an extravascular site 
of tumor growth.  It would seem obvious that  tumor-sensitized T  cells generated  in 
large numbers in vitro would  have little therapeutic  value unless  they retained  the 
capacity to perform this essential in vivo function. In this regard, a recent publication 
(13)  demonstrating  thac  mice  can  be  cured  of a  peritoneal  Friend  virus-induced 
leukemia by treatment with cyclophosphamide followed by intraperitoneal  infusion 
of Ly-1  + T cells from immune donors is therapeutically convincing, because the tumor 
had spread to blood and spleen at the time of therapy. 
Summary 
On  the  basis of preceding  studies  showing  that  tumor-induced,  T  cell-mediated 
immunosuppression serves as an obstacle tO adoptive immunotherapy of the Meth A 
fibrosarcoma, it  was  predicted  that  cyclophosphamide treatment  of tumor bearers ROBERT J.  NORTH  1073 
would remove this obstacle and allow passively transferred  immune T  cells to cause 
tumor regression.  It  was  found  that  infusion  of immune  spleen  cells  alone  had  no 
effect  on  tumor  growth,  and  cyclophosphamide  alone  caused  a  temporary  halt  in 
tumor progression.  In contrast, combination therapy consisting of intravenous injec- 
tion of 100 mg/kg of cyclophosphamide followed 1 h  later by intravenous infusion of 
tumor-immune spleen  cells caused small,  as well as large tumors,  to completely and 
permanently  regress.  Tumor  regression  caused  by  combination  therapy  was  com- 
pletely inhibited  by intravenous  infusion of splenic T  cells  from donors with estab- 
lished  tumors,  but not by spleen cells from normal donors.  These suppressor T  cells 
were eliminated from the spleen by treating the tumor-bearing donors with  100 mg/ 
kg of cyclophosphamide.  Immune T  cells, in contrast,  were resistant  to this  dose of 
cyclophosphamide.  These results  show that  failure of intravenously-infused,  tumor- 
sensitized  T  cells  to  cause  regression  of the  Meth  A  fibrosarcoma  growing  in  its 
syngeneic  or semi-syngeneic  host  is  caused  by  the  presence  of a  tumor-induced 
population of cyclophosphamide-sensitive suppressor T  cells. 
The expert technical assistance of Ronald LaCourse, Debra Klock, and Sylvia Warburton is 
gratefully acknowledged. 
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